Jump Start Workshop: Toronto Innovation Acceleration Partners (TIAP) - How to build translational potential of academic research & access early-stage funding
Event Date: January 18th, 2023 3:00-4:30PM
This event is hybrid and will be taking place in the Leslie Dan Faculty of Pharmacy Building Room 1210 (12th floor) and Zoom.
Registration is required.
The Jump Start Workshop will feature panel speakers from Toronto Innovation Acceleration Partners (TIAP) to discuss how to build translational potential of academic research and access early-stage funding. During this session, the flagship Lab150 Program drug discovery and development program will be introduced and followed by a discussion panel. The speakers will share their expertise in developing life science technologies and go over the benefits of working with TIAP, including close collaboration with industry and the investment community. You will learn how to identify and develop commercial assets in disease-related academic research, significantly shorten the drug discovery timeline, and access early-stage funding opportunities.
The goal of PRiME's Jump Start series is to ensure investigators and trainees are equipped with knowledge and skills for each step of the biotechnology development process, with the aim of facilitating the transition of academic researchers from all career stages to entrepreneurship. In the series we engage with experts to discuss important considerations to ensure success at each step of the development process, and increase collaboration between academia, government, and industry partners.
These workshops are open to all Staff, Trainees and Faculty at UofT.
Panelists
Philip Goldbach, PhD
Director, Technology and Venture Development
TIAP
Phil Goldbach combines scientific, management and intellectual property (IP) expertise to guide the development of innovative life science technologies and ventures. In his current role at TIAP, he co-manages the LAB150 Drug Discovery & Development Program, a collaboration between TIAP and Evotec SE, designed to accelerate the development of novel therapeutics based on breakthrough discoveries at the University of Toronto and its affiliated teaching hospitals. Within the program, Phil manages and acts as commercialization lead for portfolio projects in diverse therapeutic areas, including oncology, dermatology and rare disease. Prior to joining TIAP, Philwas Director of IP at a biotechnology company based in Mississauga and, prior to that, trained atan IP boutique law firm in downtown Toronto as a member of the firm’s life sciences patent practice group, with exposure to an array of technologies including biologics, small molecules, medical devices, and information technologies. Phil received his PhD in Molecular Genetics at U of T and his JD from Osgoode Hall Law School.
Ido Kaminsky, MSc
Director, Technology and Venture Development
TIAP
Ido leads scouting and project managements activities across a portfolio of early-stage therapeutics programs, as well as investments into spinouts from the TIAP Membership. Prior to TIAP, Ido served as the Director of Business Development at FutuRx, a biotech incubator established by J&J (JJDC), Takeda Ventures, and Orbimed. There, he conducted scouting, diligence, and transactional activities, and was involved in the inception of over 10 biotech start-ups. Before FutuRx, Ido spent several years with RM Global Partners, an investment bank and consulting firm in the biotech and medical-device space. There, he worked on corporate strategy and financing with clients across Israel, the US, and Korea, as well as the inception of a VC Fund. Before that, he was an Analyst at the Frankel Group, a life-science focused strategic consulting firm.
Ido holds a M.Sc. in biochemistry from the Weizmann Institute of Science, Israel.